Physician profile
Gregory G Bishop
NPI 1649278078
$9,178.05
in general payments reported to CMS, 2019-2025
26 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $415 · 2021: $688 · 2022: $622 · 2023: $3,103 · 2024: $1,274 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060 · Travel and Lodging: $1,728 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,060.16 |
| Travel and Lodging | $1,728.35 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $5,897.77 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Abiomed | $908.01 | 2019-2024 | Impella |
| Boston Scientific Corporation | $421.21 | 2019-2025 | Rhythmia Mapping System, Ekosonic, Eluvia |
| Novartis Pharmaceuticals Corporation | $324.77 | 2019-2025 | |
| Abbott Laboratories | $256.94 | 2019-2024 | Perclose Prostyle |
| Medtronic, INC. | $255.24 | 2022-2024 | Corevalve Evolut R |
| Artivion, INC. | $237.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.08 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $95.54 | 2019-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $70.13 | 2019-2025 | Camzyos |
| Pfizer INC. | $60.09 | 2019-2025 | |
| Shockwave Medical, INC | $58.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $48.96 | 2019 | |
| Scpharmaceuticals INC. | $44.04 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.23 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.61 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $32.53 | 2020-2024 | Farxiga |
| Biotronik INC. | $30.65 | 2023 | Orsiro Mission, Nhancer Rx |
| Cardiovascular Systems INC. | $24.55 | 2022 | |
| Kestra Medical Technology Services, INC. | $24.51 | 2025 | Assure Wcd |
| Acist Medical Systems, INC. | $22.92 | 2023 | |
| Cardiva Medical, INC. | $21.54 | 2025 | Savvywire |
| Lexicon Pharmaceuticals, INC. | $19.14 | 2023 | Inpefa |
| Medtronic Vascular, INC. | $18.49 | 2019 | |
| Gilead Sciences, INC. | $15.37 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.